StockNews.AI
BBIO
StockNews.AI
99 days

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

1. BridgeBio presents important acoramidis data at Heart Failure 2025. 2. Acoramidis shows benefits for quality of life in ATTR-CM patients. 3. Post-hoc analysis indicates lower atrial fibrillation risk with acoramidis. 4. New data enhance understanding of ATTR-CM disease progression. 5. Acoramidis approved for treating transthyretin-mediated amyloidosis.

6m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical data on acoramidis boosts investor confidence, similar to past drug successes.

How important is it?

The positive presentation of acoramidis at a major conference signals strong market potential.

Why Short Term?

Immediate market reactions expected around conference presentations highlighting acoramidis' effectiveness.

Related Companies

AMRNPRTAALNY
May 12, 2025 07:30 ET  | Source: BridgeBio Pharma, Inc. PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality of life measures provided by acoramidis in variant transthyretin amyloid cardiomyopathy (ATTR-CM) and one moderated ePoster on a post-hoc analysis of the lower incidence rate of atrial fibrillation-related events in patients with ATTR-CM, all from the ATTRibute-CM study will be shared at the Annual Congress of the Heart Failure Association of the ESC (Heart Failure 2025), taking place in Belgrade, Serbia on May 17 - 20, 2025. In addition to the four abstracts, three moderated ePosters will be shared on the disease progression of ATTR-CM in a real-world setting, a retrospective cohort study on manifestation to diagnosis of ATTR-CM, and data on the cause of death of ATTR-CM patients in the ATTRibute-CM study. Rapid-fire Abstract Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CMPresenter: Anique Ducharme, M.D., Université de Montréal, CANDate: Tuesday, May 20 at 8:30 am CEST/2:30 am ET Moderated ePosters: Effect of Acoramidis on Functional Capacity and Quality of Life in Patients with Variant ATTR-CM: Results from ATTRibute-CMPresenter: Marianna Fontana, M.D., University College London, UKDate: Sunday, May 18 at 11:00 am CEST/5:00 am ET Effect of Acoramidis on All-cause Mortality, Cardiovascular Hospitalization and NT-proBNP in Variant ATTR-CM: Results from ATTRibute-CMPresenter: Marianna Fontana, M.D., University College London, UKDate: Sunday, May 18 at 11:00 am CEST/5:00 am ET Acoramidis Treatment Is Associated with a Lower Incidence of Atrial Fibrillation-related Events in Patients with ATTR-CM: A Post Hoc Analysis of the ATTRibute-CM trialPresenter: Kevin Alexander, M.D., Stanford University School of Medicine, USADate: Sunday, May 18 at 11:00 am CEST/5:00 am ET Disease Progression Among Patients Receiving Tafamidis for ATTR-CM in a Real-world SettingPresenter: Daniel P. Judge, M.D., Medical University of South Carolina, USA Date: Sunday, May 18 at 11:00 am CEST/5:00 am ET Cause of Death in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings from the ATTRibute-CM studyPresenter: Laura Obici, M.D., University of Pavia, ESPDate: Sunday, May 18 at 11:00 am CEST/5:00 am ET Time from First Recorded Clinical Manifestation to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using U.S. Claims DataPresenter: Joshua Mitchell, M.D., Washington University School of Medicine in St. Louis, USADate: Sunday, May 18 at 11:00 am CEST/5:00 am ET About Attruby™ (acoramidis) INDICATION Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. IMPORTANT SAFETY INFORMATION Adverse Reactions Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively). About BridgeBioBridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube. BridgeBio Media Contact:Bubba Murarka, EVP Communicationscontact@bridgebio.com (650)-789-8220 BridgeBio Investor Contact:Chinmay Shukla, VP Strategic Financeir@bridgebio.com

Related News